查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012553

人工尿道括约肌市场：按类型、性别、分销管道、应用和最终用户划分－2026年至2032年全球市场预测

Artificial Urinary Sphincters Market by Type, Gender, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人工尿道括约肌市场价值将达到 4.6099 亿美元，到 2026 年将成长至 4.9751 亿美元，到 2032 年将达到 7.6318 亿美元，年复合成长率为 7.46%。

主要市场统计数据
基准年 2025 460,990,000 美元
预计年份：2026年 4.9751亿美元
预测年份 2032 7.6318亿美元
复合年增长率 (%) 7.46%

人工尿道括约肌权威指引：系统性地说明了临床必要性、设备发展历程以及医疗系统和设备开发人员的策略考量。

人工尿道括约肌（AUS）在泌尿系统、外科医疗设备创新和以患者为中心的排尿管理领域占据着策略性的关键地位。这些器械最初旨在帮助应力性尿失禁和神经源性膀胱功能障碍患者恢復排尿控制能力，并随着材料科学、外科技术和门诊护理模式的进步而不断发展。临床需求显而易见：恢復可靠的排尿功能能够显着提高患者的生活质量，减轻看护者的负担，并减少持续性尿失禁患者长期照护的需求。

随着临床实践、设备工程和护理服务模式的融合，关键趋势正在重塑人工尿道括约肌领域，并影响人工尿道括约肌的普及应用。

人工尿道括约肌领域正经历一场变革，这得益于临床、技术和治疗模式三方面因素的融合。首先，随着临床医师采用更严格的表型分析和共用决策框架，患者选择标准日趋成熟，长期治疗效果不断提升，再次手术率持续下降。其次，器械工程正朝着模组化和材料改良的方向发展，透过简化手术技巧，缩短了外科医师进行植入手术的学习曲线，同时最大限度地减少了侵蚀和感染的风险。

对2025年生效的美国关税对尿道括约肌相关人员的供应链策略、生产本地化和采购决策的影响的实用分析

美国计划于2025年实施的关税为涉及相关人员尿道括约肌等医疗设备的供应链和采购决策带来了新的不稳定性。关税带来的成本压力尤其影响海外生产的器械和零件的筹资策略。因此，製造商正在重新评估其供应商名单，以降低关税上涨带来的风险，并在保持价格竞争力的同时维持利润率，从而吸引医疗服务提供者。

详细的細項分析解释了医疗设备类型、最终用户环境、分销管道、性别差异和临床应用如何共同影响商业化和临床应用。

市场区隔洞察揭示了决定人工尿道括约肌临床适用性、商业化策略和分销复杂性的关键因素。根据类型，该领域可分为单组件、三组件和双组件设计，每种设计都代表不同的手术流程、再次手术风险以及对植入医生的培训要求。单组件系统倾向于优先考虑简便性，而三组件解决方案则在可调节性和生理模拟性之间寻求平衡，双组件则探索了器械复杂性和手术效率之间的折衷方案。

一份全面的区域分析报告，描述了美洲、欧洲、中东和非洲以及亚太地区在设备部署的临床、监管和商业性路径上的差异。

人工尿道括约肌的区域趋势各不相同，并受到全球主要市场医疗基础设施、报销机制和手术实施模式的影响。在美洲，先进的泌尿系统护理、大量的门诊手术以及保险公司对长期治疗效果和成本效益的重视，正在塑造着人工尿道括约肌的普及趋势。该地区的临床医生通常在产生比较性临床证据和製定最佳实践手术方案方面发挥主导作用，这反过来又会影响商业策略和产品定位。

关键的公司层面洞察揭示了临床证据、製造策略、培训计划和策略伙伴关係如何在尿道括约肌市场中创造可持续的差异化优势。

在人工尿道括约肌领域，各公司之间的竞争格局主要体现在透过临床证据、器械可靠性、手术可操作性和综合支持服务实现差异化。主要企业优先考虑长期疗效数据、外科医生培训项目和上市后监测，以证明产品的耐用性和安全性。此外，投资于微创植入技术和简化操作机制的公司可以缩短手术时间，并扩大可进行植入手术的临床医生群体。

为医疗器材製造商和医疗保健系统提供策略和营运建议，以建立临床证据，从而加速部署、保护利润率并支持采购决策。

产业领导企业应推动一系列务实倡议，以平衡临床价值、永续的商业性收入和营运韧性。首先，他们应优先透过註册登记和多中心观察性研究产生高品质的真实世界数据 (REW) 和病患报告结局 (PRO)，以支持其价值主张，并有助于与支付方和医院采购团队进行谈判。其次，他们应优化器械设计和包装，以缩短手术时间并简化库存管理，从而赢得门诊手术中心和高周转率诊所的支援。

为了支持研究结果，我们需要对研究途径进行透明的解释，该方法结合了临床文献的整合、与相关人员的访谈、治疗流程图绘製和供应链情境分析。

本报告的调查方法结合了系统性文献综述、相关人员访谈、医疗设备流程图绘製以及监管和支付框架的整合，旨在建立稳健的证据基础进行分析。研究人员对临床文献和指南资讯来源进行了交叉检验，并结合对植入外科医生、采购经理和分销合作伙伴的访谈，深入了解实际决策因素和营运限制。流程图绘製记录了门诊手术中心、诊所和医院的具体需求，从而能够评估医疗设备的适用性和手术全期资源需求。

总之，综合分析强调了临床证据、设备设计和供应链韧性之间的关键交互作用，这决定了长期的成功和对患者的影响。

总之，人工尿道括约肌仍然是临床上至关重要的治疗方法，随着器材创新、证据累积和医疗服务模式的转变，其应用前景也日益广阔。未来的普及取决于製造商能否证明其产品具有持续的临床疗效，设计出能够简化手术流程的植入，并调整经营模式以适应不同终端用户环境下的采购实际情况。价格压力和供应链风险凸显了营运柔软性和策略性供应商选择的重要性，以维持市场准入和竞争优势。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 人工尿道括约肌市场：依类型划分

  • 单组分
  • 3个组成部分
  • 2 个组件

第九章 人工尿道括约肌市场：性别

  • 女士
  • 男性

第十章：人工尿道括约肌市场：依通路划分

  • 直销
    • 我们的销售团队
    • OEM销售团队
  • 销售代理
    • 线上平台
    • 第三方经销商

第十一章 人工尿道括约肌市场：依应用领域划分

  • 神经源性膀胱功能障碍
  • 应力性尿失禁

第十二章：人工尿道括约肌市场：依最终用户划分

  • 门诊手术中心
    • 独立的
    • 医院附属机构
  • 诊所
    • 全科诊所
    • 泌尿系统诊所
  • 医院
    • 私立医院
    • 公立医院

第十三章 人工尿道括约肌市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 人工尿道括约肌市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 人工尿道括约肌市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国：人工尿道括约肌市场

第十七章 中国：人工尿道括约肌市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Affluent Medical
  • Albyn Medical Ltd.
  • Andromeda Medizinische Systeme GmbH
  • Anhui Longterm Medical Products Co., Ltd.
  • Boston Scientific Corporation
  • Coloplast A/S
  • CooperSurgical Inc.
  • Dualis MedTech GmbH
  • GT Urological LLC
  • LABORIE Medical Technologies Inc.
  • MyoPowers Medical Technologies SAS
  • Promedon SA
  • Rigicon Inc.
  • Uromedical AG
  • Zephyr Surgical Implants AG
Product Code: MRR-432CBFF6F3AA

The Artificial Urinary Sphincters Market was valued at USD 460.99 million in 2025 and is projected to grow to USD 497.51 million in 2026, with a CAGR of 7.46%, reaching USD 763.18 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 460.99 million
Estimated Year [2026] USD 497.51 million
Forecast Year [2032] USD 763.18 million
CAGR (%) 7.46%

A definitive introduction to artificial urinary sphincters that frames clinical imperatives, device evolution, and strategic considerations for health systems and device developers

Artificial urinary sphincters (AUS) occupy a strategic intersection between urology, surgical device innovation, and patient-centered continence management. Historically designed to restore urinary control for patients affected by stress urinary incontinence and neurogenic bladder dysfunction, these devices have evolved in parallel with advances in materials science, surgical technique, and outpatient care models. The clinical imperative is clear: reliable continence restoration materially improves quality of life, reduces caregiver burden, and decreases long-term care needs for patients with persistent incontinence.

Clinicians now approach device selection with a more nuanced appreciation of patient phenotype, device ergonomics, and the downstream implications for infection prevention and revision procedures. Consequently, manufacturers are competing not only on implant performance but on ease of implantation, postoperative management pathways, and integrated training for surgeons. From a stakeholder perspective, hospitals and ambulatory surgical centers are evaluating the total cost of care implications of AUS implantation, weighing upfront procedural resource requirements against long-term reductions in incontinence-associated therapies and readmissions.

Transitioning from legacy devices to newer designs requires evidence that addresses safety, durability, and patient-reported outcomes in real-world settings. As a result, cross-functional teams spanning clinical research, regulatory affairs, and commercial operations must align to accelerate adoption. In this context, the introduction to artificial urinary sphincters is best framed as an ongoing process of clinical validation, health system integration, and iterative device refinement that will shape adoption trajectories over the coming years.

Critical transformative trends reshaping the artificial urinary sphincter landscape as clinical practice, device engineering, and care delivery models converge to influence adoption

The landscape for artificial urinary sphincters is undergoing transformative shifts driven by converging clinical, technological, and delivery-model forces. First, patient selection has matured as clinicians adopt more rigorous phenotyping and shared decision-making frameworks, which improves long-term outcomes and reduces revision rates. Second, device engineering has moved toward modularity and refinement of materials to minimize erosion and infection while simplifying surgical technique, thereby shortening learning curves for implanting surgeons.

Concurrently, the rise of ambulatory surgical centers and their increasing role in elective urological procedures is reshaping procedure economics and perioperative protocols. These sites demand devices that enable efficient implantation and predictable recovery pathways. Moreover, digital health integration is beginning to influence postoperative monitoring, enabling remote collection of patient-reported outcomes and early detection of complications, which supports safer outpatient management.

Regulatory pathways are also evolving, with greater emphasis on post-market surveillance and real-world evidence to demonstrate device safety and effectiveness. This shift encourages manufacturers to invest in longitudinal registries and robust evidence generation strategies. Finally, payer and hospital procurement stakeholders now place higher priority on demonstrable improvements in quality metrics and reductions in downstream resource utilization. Together, these shifts create an environment in which clinical evidence, surgical ergonomics, and delivery-site fit determine winners and laggards in the AUS ecosystem.

Practical analysis of how the United States tariffs effective in 2025 influence supply chain strategies, production localization, and procurement decisions for urinary sphincter stakeholders

The imposition of United States tariffs scheduled for 2025 has introduced a new variable into supply chain and procurement decision-making for medical device stakeholders involved with artificial urinary sphincters. Tariff-driven cost pressures affect component sourcing strategies, especially for devices or subcomponents produced internationally. As a consequence, manufacturers are reassessing supplier footprints to mitigate exposure to tariff escalations and to preserve margin while maintaining competitive pricing for healthcare providers.

In response, some device firms are accelerating near-shoring initiatives, shifting assembly or critical component production closer to core markets to reduce tariff pass-through and improve supply-chain resilience. Others are pursuing strategic supplier diversification to avoid single points of failure and to gain leverage in contract negotiations. Hospitals and ambulatory surgical centers are also adjusting procurement practices, engaging in more rigorous total cost of ownership assessments that incorporate potential tariff variability and logistics risk premiums.

Importantly, tariff-related shifts ripple beyond direct cost implications. Manufacturers with vertically integrated supply chains or flexible production capacity will find it easier to absorb or offset tariff impacts, whereas smaller suppliers may face margin compression that limits their ability to invest in product improvements or evidence generation. In turn, clinicians and health systems should expect to see a gradual repricing of devices, a recalibration of distributor contracts, and a stronger focus on long-term value metrics when negotiating purchasing agreements in the post-tariff environment.

Deep segmentation analysis explaining how device type, end-user settings, distribution channels, gender differences, and clinical applications jointly shape commercialization and clinical adoption

Segmentation insights reveal critical levers that determine clinical fit, commercialization tactics, and distribution complexity for artificial urinary sphincters. Based on Type, the field differentiates among Single Component, Three Component, and Two Component designs, each presenting distinct surgical workflows, revision risk profiles, and training needs for implanting clinicians. Single component systems often emphasize simplicity, while three component solutions aim to balance adjustability and physiological mimicry, and two component variants seek compromise between device complexity and procedural efficiency.

Based on End User, adoption dynamics vary across Ambulatory Surgical Centers, Clinics, and Hospitals. Ambulatory Surgical Centers are further differentiated into Freestanding and Hospital Affiliated models, both of which prioritize throughput and predictable perioperative pathways. Clinics are categorized into Multispecialty Clinics and Urology Clinics, and these settings influence referral patterns, patient counseling practices, and follow-up care models. Hospitals, divided into Private Hospitals and Public Hospitals, bring differing procurement governance, purchasing cycles, and risk tolerance that affect device selection and contract negotiations.

Based on Distribution Channel, strategies range from Direct Sales to Distributors. The Direct Sales route includes In House Sales Force and OEM Sales Force approaches that enable tighter clinical training and closer customer relationships, whereas Distributors encompass Online Platforms and Third Party Distributors that provide broader geographic reach and logistical scale. Based on Gender, device uptake, surgical approach, and rehabilitative needs vary across Female and Male patient groups, prompting manufacturers to tailor design considerations and outcome measurement. Finally, based on Application, clinical use cases separate into Neurogenic Bladder Dysfunction and Stress Urinary Incontinence, with each indication driving different evidence requirements, patient management pathways, and reimbursement conversations.

Comprehensive regional intelligence describing how Americas, Europe Middle East & Africa, and Asia-Pacific each present distinct clinical, regulatory, and commercial pathways for device adoption

Regional dynamics for artificial urinary sphincters are heterogeneous and influenced by healthcare infrastructure, reimbursement mechanisms, and surgical practice patterns across major global markets. In the Americas, adoption is shaped by advanced urological practice, significant outpatient procedural volumes, and payer scrutiny that emphasizes long-term outcomes and cost-effectiveness. Clinicians in this region often lead in generating comparative clinical evidence and establishing best-practice surgical protocols, which in turn influences commercial strategies and product positioning.

Europe, Middle East & Africa presents a diverse landscape where centralized reimbursement decisions in some countries contrast with fragmented payer systems in others. Procurement cycles and hospital purchasing strategies differ markedly, requiring tailored market access plans and acute attention to regulatory harmonization and post-market requirements. Training programs and registry participation are often critical levers for establishing clinical credibility in this region.

Asia-Pacific encompasses markets with rapidly expanding surgical capacity, growing demand for minimally invasive and outpatient procedures, and increasing investments in local manufacturing and regulatory maturity. The region's heterogeneity also means that device sponsors must calibrate pricing strategies and distribution partnerships to local procurement norms, hospital networks, and rising patient awareness of advanced continence interventions. Across all regions, the interplay of clinical evidence, cost considerations, and distribution effectiveness determines the pace and pattern of adoption.

Key company-level insights that illuminate how clinical evidence, manufacturing strategy, training programs, and strategic partnerships create durable differentiation in the urinary sphincter market

Competitive dynamics among companies operating in the artificial urinary sphincter arena center on differentiation through clinical evidence, device reliability, surgical ergonomics, and integrated support services. Leading firms prioritize long-term outcome data, surgeon training programs, and post-market surveillance to demonstrate durability and safety. In addition, companies investing in minimally invasive implantation techniques and simplified actuation mechanisms can reduce procedure times and broaden the pool of implanting clinicians.

Partnerships and strategic collaborations are increasingly important, with device makers aligning with specialist distributors, health systems, and clinical investigators to accelerate device visibility and generate real-world evidence. Some companies focus on vertical integration to secure supply chain stability and to protect margins, while others opt for agile manufacturing models that allow rapid iteration of design improvements.

Service offerings such as comprehensive surgeon training, patient education resources, and registry participation enhance commercial value propositions and build long-term brand trust among urology communities. Finally, firms that embed clinician feedback into iterative product roadmaps and that can demonstrate tangible reductions in revision rates and complication incidence will be better positioned to secure formulary placements and preferred supplier status within health systems.

Strategic and operational recommendations for device makers and health systems to accelerate adoption, protect margins, and build clinical evidence that drives procurement decisions

Industry leaders should pursue a set of actionable initiatives that align clinical value with sustainable commercial returns and operational resilience. First, prioritize generation of high-quality real-world evidence and patient-reported outcomes through registries and multicenter observational studies to underpin value claims and to support negotiations with payers and hospital procurement teams. Second, optimize device design and packaging to reduce operative time and streamline inventory management, which will resonate with ambulatory surgical centers and high-throughput clinics.

Third, diversify and near-shore supply chains to mitigate tariff exposure, logistics disruption, and component scarcity, thereby protecting margins and ensuring reliable product availability. Fourth, deploy specialized surgeon training programs that shorten learning curves and create clinical champions who can advocate for device adoption within their institutions. Fifth, tailor commercial approaches by end-user segment and regional nuance, ensuring that pricing, reimbursement support, and service models match the procurement practices of Freestanding Ambulatory Surgical Centers, Hospital Affiliated centers, Multispecialty Clinics, Urology Clinics, Private Hospitals, and Public Hospitals.

Finally, integrate digital follow-up tools that collect longitudinal patient outcomes to support safety surveillance and to demonstrate reductions in revision rates and downstream resource utilization. By executing these measures, industry leaders can improve adoption velocity, enhance clinical outcomes, and create defensible commercial positions in a competitive landscape.

Transparent explanation of research approach combining clinical literature synthesis, stakeholder interviews, procedural pathway mapping, and supply chain scenario analysis to support the findings

The research methodology underpinning this report combined systematic literature appraisal, stakeholder interviews, device procedural pathway mapping, and synthesis of regulatory and payer frameworks to create a robust evidence base for analysis. Clinical literature and guideline sources were triangulated with interview insights from implanting surgeons, procurement leaders, and distribution partners to capture real-world decision drivers and operational constraints. Procedural pathway mapping documented site-specific requirements across ambulatory surgical centers, clinics, and hospitals, enabling assessment of device fit and perioperative resource needs.

Supplier and distribution channel analysis examined both direct sales models and distributor ecosystems to evaluate strengths and limitations in training, logistical capacity, and market reach. Regulatory pathway reviews highlighted post-market evidence expectations and surveillance mechanisms that influence product lifecycle planning. Finally, scenario analysis explored the impacts of supply-chain shocks and tariff changes on production strategies and procurement dynamics, which informed actionable recommendations for near-term resilience and long-term strategic positioning.

Concluding synthesis highlighting the critical interplay of clinical evidence, device design, and supply chain resilience that will determine long-term success and patient impact

In conclusion, artificial urinary sphincters remain a clinically vital intervention with evolving opportunities driven by device innovation, evidence generation, and shifting care delivery models. The future trajectory of adoption will hinge on the ability of manufacturers to demonstrate durable clinical outcomes, to design implants that simplify surgical workflows, and to align commercial models with the procurement realities of diverse end-user settings. Tariff pressures and supply-chain risks underscore the need for operational agility and strategic supplier choices to maintain access and competitive positioning.

Clinicians, hospital leaders, and device developers who invest in longitudinal evidence collection, targeted surgeon training, and adaptive distribution strategies will be best positioned to translate technological advances into sustained patient benefit. A disciplined focus on total cost of care, paired with clear communication of outcomes and value, will accelerate acceptance among payers and purchasing committees. Ultimately, success in this space will require coordinated efforts across clinical, regulatory, and commercial functions to ensure that device innovations reach patients reliably and safely, delivering measurable improvements in continence and quality of life.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Urinary Sphincters Market, by Type

  • 8.1. Single Component
  • 8.2. Three Component
  • 8.3. Two Component

9. Artificial Urinary Sphincters Market, by Gender

  • 9.1. Female
  • 9.2. Male

10. Artificial Urinary Sphincters Market, by Distribution Channel

  • 10.1. Direct Sales
    • 10.1.1. In House Sales Force
    • 10.1.2. Oem Sales Force
  • 10.2. Distributors
    • 10.2.1. Online Platforms
    • 10.2.2. Third Party Distributors

11. Artificial Urinary Sphincters Market, by Application

  • 11.1. Neurogenic Bladder Dysfunction
  • 11.2. Stress Urinary Incontinence

12. Artificial Urinary Sphincters Market, by End User

  • 12.1. Ambulatory Surgical Centers
    • 12.1.1. Freestanding
    • 12.1.2. Hospital Affiliated
  • 12.2. Clinics
    • 12.2.1. Multispecialty Clinics
    • 12.2.2. Urology Clinics
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals

13. Artificial Urinary Sphincters Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Urinary Sphincters Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Urinary Sphincters Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Urinary Sphincters Market

17. China Artificial Urinary Sphincters Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Affluent Medical
  • 18.6. Albyn Medical Ltd.
  • 18.7. Andromeda Medizinische Systeme GmbH
  • 18.8. Anhui Longterm Medical Products Co., Ltd.
  • 18.9. Boston Scientific Corporation
  • 18.10. Coloplast A/S
  • 18.11. CooperSurgical Inc.
  • 18.12. Dualis MedTech GmbH
  • 18.13. GT Urological LLC
  • 18.14. LABORIE Medical Technologies Inc.
  • 18.15. MyoPowers Medical Technologies SAS
  • 18.16. Promedon S.A.
  • 18.17. Rigicon Inc.
  • 18.18. Uromedical AG
  • 18.19. Zephyr Surgical Implants AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY SINGLE COMPONENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY SINGLE COMPONENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY SINGLE COMPONENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THREE COMPONENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THREE COMPONENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THREE COMPONENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TWO COMPONENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TWO COMPONENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TWO COMPONENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY IN HOUSE SALES FORCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY IN HOUSE SALES FORCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY IN HOUSE SALES FORCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY OEM SALES FORCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY OEM SALES FORCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY OEM SALES FORCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY NEUROGENIC BLADDER DYSFUNCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY NEUROGENIC BLADDER DYSFUNCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY NEUROGENIC BLADDER DYSFUNCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY STRESS URINARY INCONTINENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY STRESS URINARY INCONTINENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY STRESS URINARY INCONTINENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FREESTANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FREESTANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FREESTANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITAL AFFILIATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITAL AFFILIATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITAL AFFILIATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MULTISPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MULTISPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)